Latest News and Press Releases

NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™...

NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...

NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...

NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice...

NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...

NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...

NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...

 Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company...

NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...

NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...